Hims & Hers Health (NYSE:HIMS) Shares Down 5% After Analyst Downgrade

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) shares traded down 5% during mid-day trading on Tuesday after Truist Financial lowered their price target on the stock from $48.00 to $37.00. Truist Financial currently has a hold rating on the stock. Hims & Hers Health traded as low as $43.21 and last traded at $42.84. 6,014,452 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 33,741,582 shares. The stock had previously closed at $45.10.

A number of other research firms also recently commented on HIMS. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Piper Sandler restated a "neutral" rating and issued a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Bank of America increased their price target on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a report on Tuesday, April 29th. TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their price target for the stock from $44.00 to $30.00 in a report on Tuesday, April 29th. Finally, Morgan Stanley reaffirmed an "equal weight" rating and set a $40.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Two research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Hims & Hers Health presently has a consensus rating of "Reduce" and an average target price of $38.92.

Insider Buying and Selling

In other news, insider Michael Chi sold 2,100 shares of the stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $57.52, for a total transaction of $120,792.00. Following the completion of the sale, the insider owned 278,654 shares of the company's stock, valued at approximately $16,028,178.08. This represents a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Soleil Boughton sold 2,572 shares of the company's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $51.64, for a total transaction of $132,818.08. Following the completion of the transaction, the insider owned 153,021 shares of the company's stock, valued at $7,902,004.44. This trade represents a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,273,034 shares of company stock worth $66,425,573. 17.71% of the stock is owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several large investors have recently modified their holdings of the stock. Smartleaf Asset Management LLC raised its position in shares of Hims & Hers Health by 15.7% in the 1st quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company's stock worth $49,000 after purchasing an additional 227 shares during the last quarter. Bessemer Group Inc. lifted its position in shares of Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company's stock valued at $30,000 after buying an additional 312 shares in the last quarter. True Vision MN LLC lifted its holdings in Hims & Hers Health by 3.6% in the 2nd quarter. True Vision MN LLC now owns 9,376 shares of the company's stock worth $467,000 after purchasing an additional 328 shares in the last quarter. Allworth Financial LP lifted its holdings in Hims & Hers Health by 20.0% in the 1st quarter. Allworth Financial LP now owns 2,006 shares of the company's stock worth $56,000 after purchasing an additional 334 shares in the last quarter. Finally, Signaturefd LLC raised its holdings in shares of Hims & Hers Health by 17.7% during the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company's stock worth $76,000 after acquiring an additional 388 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Stock Down 4.7%

The firm has a market capitalization of $9.72 billion, a PE ratio of 53.60, a PEG ratio of 2.91 and a beta of 2.08. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. The company has a fifty day moving average price of $52.72 and a 200-day moving average price of $45.77.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business's revenue for the quarter was up 72.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.